Navigation Links
Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
Date:8/19/2010

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million.

Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent that has demonstrated promising antitumor activity in Phase 1 and Phase 2 clinical trials.

"This important round of financing provides us with funds necessary to continue to advance our pipeline of promising oncology products through clinical development and to achieve a number of corporate and clinical milestones.  This includes the completion of the ongoing JX-594 Phase 2 clinical trials currently underway for patients with liver cancer and colorectal cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We appreciate the support from many of our existing stockholders as well as a number of new important investors who chose to participate in this successful financing."

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diver
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
2. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
3. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
6. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
9. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
10. Resverlogix Completes Dosing for ASSERT Trial
11. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... WI (PRWEB) April 25, 2015 Join ... April 29th: Analyzing Kinase Inhibitor Residence Times using the ... Analysis of inhibitor residence times is increasingly being incorporated ... target can result in improved efficacy, increased therapeutic window ... be determined using immobilized ligand methods such surface plasmon ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Top student ... other San Diego area universities, including UCSD and SDSU, ... judges from prominent local, national and nonprofit companies for ... the 5th Annual Social Innovation Challenge 2015 . ... unique social venture ideas addressing a diverse range of ...
(Date:4/24/2015)... SD and Tempe, AZ (PRWEB) April 24, 2015 ... Technology and Arizona State University (ASU) have entered into ... joint projects. , A memorandum of agreement signed by ... long distance learning, student success and other services particularly, ... resources. , “We have complementary strengths and a ...
(Date:4/24/2015)... April 24, 2015 Leading Regenerative ... in its allogeneic stem-cell product development program and ... reflect the corporate strategic direction. , “I am ... adipose stem cell development program has been kicked ... cGMP manufacturing facility and hiring of our new ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2
... TRIANGLE PARK, N.C., Jan. 24 Quintiles,Transnational Corp. ... investor partnership to support the company,s continued,growth under ... CEO Dennis,Gillings, CBE, and the management team. Gillings ... Capital have become the lead,investors in Quintiles, with ...
... BOHEMIA, N.Y., Jan. 23 NBTY, Inc. (NYSE: NTY ... nutritional,supplements, today announced it will web cast a conference call ... http://www.nbty.com on,Monday, January 28, 2008 at 8:30 AM ... will be issued at 7:00 AM (ET) that,day., A ...
... PPD, Inc. (Nasdaq:,PPDI) today announced that it ... through an exclusive agreement with Peking Union Lawke,Biomedical ... begin,immediately providing biopharmaceutical clients with its full range ... "Chinese law makes it extremely difficult to export ...
Cached Biology Technology:Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3NBTY to Web Cast Fiscal First Quarter Conference Call 2PPD Expands Global Central Lab Services into China 2PPD Expands Global Central Lab Services into China 3
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... in stores or order in restaurants, the chance that an individual ... causes. This may seem obvious to most (they had to get ... that the relentless pursuit of consumer-friendly fish product is having a ... only the biggest fish, or only those found in certain habitats, ...
... to assessing risk for type 2 diabetes, not only do waistlines ... cells. This new discovery by a team of Swedish researchers ... and helps explain why some women of normal weight develop type ... knowledge of the link between enlarged fat cells and the development ...
... MONTREAL, CN (September 10, 2009) Recent research to ... constricts blood vessels and stimulates cell growth, has led ... hope for treating other chronic diseases. The usefulness of ... much less clear, said Professor Matthias Barton, M.D. of ...
Cached Biology News:Changing the course of nature: Are fisheries directing the evolution of fish populations? 2Size of fat cells and waist size predict type 2 diabetes in women 2Endothelin drugs benefit those with pulmonary hypertension 2Endothelin drugs benefit those with pulmonary hypertension 3
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
GOAT ANTI SLI...
Protein Phosphorylation...
ANTI L-DOPA...
Biology Products: